中文 | English
Return
Total: 6 , 1/1
Show Home Prev Next End page: GO
MeSH:(Antineoplastic Agents, Hormonal/adverse effects/therapeutic use)

1.GnRH Agonist Therapy to Protect Ovarian Function in Young Korean Breast Cancer Patients.

Hyun Jung PARK ; Young Ah KOO ; Young Hyuck IM ; Byung Koo YOON ; DooSeok CHOI

Journal of Korean Medical Science 2010;25(1):110-116

2.Comparative study of transvaginal ultrasonographic and diagnostic hysteroscopic findings in postmenopausal breast cancer patients treated with tamoxifen.

Wan-li GAO ; Lu-ping ZHANG ; Li-min FENG

Chinese Medical Journal 2011;124(15):2335-2339

3.Therapeutic options for management of endometrial hyperplasia.

Vishal CHANDRA ; Jong Joo KIM ; Doris Mangiaracina BENBROOK ; Anila DWIVEDI ; Rajani RAI

Journal of Gynecologic Oncology 2016;27(1):e8-

4.A Prospective, Multicenter, Open-label Trial of Zoledronic Acid in Patients with Hormone Refractory Prostate Cancer.

Sung Joon HONG ; Kang Su CHO ; Han Yong CHO ; Hanjong AHN ; Choung Soo KIM ; Byung Ha CHUNG

Yonsei Medical Journal 2007;48(6):1001-1008

5.Assessment of Breast Cancer Patients' Knowledge and Decisional Conflict Regarding Tamoxifen Use.

Se Ik KIM ; Yumi LEE ; Yedong SON ; So Yeun JUN ; Sooin YUN ; Hyo Sook BAE ; Myong Cheol LIM ; So Youn JUNG ; Jungnam JOO ; Eun Sook LEE

Journal of Korean Medical Science 2015;30(11):1604-1611

6.Anemia in patients on combined androgen block therapy for prostate cancer.

Li-Xin QIAN ; Li-Xin HUA ; Hong-Fei WU ; Yuan-Geng SUI ; Shuang-Guan CHENG ; Wei ZHANG ; Jie LI ; Xin-Ru WANG

Asian Journal of Andrology 2004;6(4):383-384

Sort by Result Analysis

Display Mode

Output Records




File Type





Total: 6 , 1/1 Show Home Prev Next End page: GO